share_log

Roth MKM Maintains Buy on Evogene, Raises Price Target to $6

Benzinga ·  Jul 22, 2023 01:18

Roth MKM analyst Brian Wright maintains Evogene (NASDAQ:EVGN) with a Buy and raises the price target from $1 to $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment